(Circulation. 1997;96:2137-2143.)
© 1997 American Heart Association, Inc.
Articles |
Prevention of the Angiographic Progression of Coronary and Vein-Graft Atherosclerosis by Gemfibrozil After Coronary Bypass Surgery in Men With Low Levels of HDL Cholesterol
From the Department of Medicine, Helsinki University Central Hospital (M.H.F., M.S., M.S.N., M-R.T.); Department of Medicine, Oulu University Hospital (H.K., Y.A.K.); and Department of Medicine, Tampere University Hospital (S.M., V.V., A.P.), Finland.
Background Studies have shown that treatment of hyperlipidemia, especially lowering of plasma LDL levels, retards the progression of coronary atherosclerosis and prevents clinical cardiovascular events. No such studies have focused on subjects with low levels of HDL cholesterol.
Methods and Results We randomly assigned 395
post–coronary bypass men, who had an HDL
cholesterol concentration 
1.1 mmol/L and LDL
cholesterol 4.5 mmol/L, to receive gemfibrozil 1200
mg/d or placebo. Coronary angiography was performed at baseline
and after, on average, 32 months of therapy. Changes in
coronary dimensions were assessed by computer-assisted
analysis. Average on-trial serum triglyceride
concentrations were 1.69±0.68 and 1.02±0.37, total
cholesterol 5.48±0.68 and 4.83±0.63, LDL
cholesterol 3.84±0.59 and 3.39±0.56, and HDL
cholesterol 0.88±0.15 and 0.98±0.17 mmol/L in the
placebo and gemfibrozil groups, respectively (mean±SD, each
P<.001). The change in per-patient means of average
diameters of native coronary segments was –0.04±0.11 mm
in the placebo group and –0.01±0.10 mm in the gemfibrozil group
(P=.009). The equivalent changes in minimum luminal
diameters of stenoses were –0.09±0.18 and –0.04±0.15
mm, respectively (P=.002). A similar, albeit nonsignificant,
trend toward treatment benefit was found in the predefined primary
study end point, segments unaffected by grafts and those distal to
graft insertions. In aortocoronary bypass grafts, 23 subjects
(14%) assigned to placebo had new lesions in the follow-up angiogram,
compared with 4 subjects (2%) assigned to gemfibrozil
(P<.001).
Conclusions Gemfibrozil therapy retarded the progression of coronary atherosclerosis and the formation of bypass-graft lesions after coronary bypass surgery in men with low HDL cholesterol as their main lipid abnormality.
Key Words: coronary disease • bypass • lipoproteins • angiography • trials
This article has been cited by other articles:
 |
|
 |
|
  E. Gongora and T. M. Sundt III Myocardial Revascularization with Cardiopulmonary Bypass Card. Surg. Adult, January 1, 2008; 3(2008): 599 - 632. [Full Text]
|
|
|
|
 |
|
 I. M. Singh, M. H. Shishehbor, and B. J. Ansell High-Density Lipoprotein as a Therapeutic Target: A Systematic Review JAMA, August 15, 2007; 298(7): 786 - 798. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Garg and V. Simha Update on Dyslipidemia J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1581 - 1589. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Freeman, A. L. Drake, L. F. Heilig, M. Graber, K. McNealy, L. M. Schilling, and R. P. Dellavalle Statins, Fibrates, and Melanoma Risk: a Systematic Review and Meta-analysis. J Natl Cancer Inst, November 1, 2006; 98(21): 1538 - 1546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Gilde, J.-C. Fruchart, and B. Staels Peroxisome Proliferator-Activated Receptors at the Crossroads of Obesity, Diabetes, and Cardiovascular Disease J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A24 - A32. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Wierzbicki Diabetic dyslipidaemia: the triad Eur. Heart J. Suppl., October 1, 2006; 8(suppl_F): F30 - F33. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Zambon, P. Gervois, P. Pauletto, J.-C. Fruchart, and B. Staels Modulation of Hepatic Inflammatory Risk Markers of Cardiovascular Diseases by PPAR-{alpha} Activators: Clinical and Experimental Evidence Arterioscler Thromb Vasc Biol, May 1, 2006; 26(5): 977 - 986. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M J. Chapman Review: Fibrates: therapeutic review The British Journal of Diabetes & Vascular Disease, January 1, 2006; 6(1): 11 - 19. [Abstract] [PDF]
|
|
|
|
|
|
L. F Van Gaal, F. Peiffer, and D. Ballaux Reducing cardiovascular risk in patients with type 2 diabetes: the potential contribution of nicotinic acid The British Journal of Diabetes & Vascular Disease, November 1, 2005; 5(6): 344 - 350. [Abstract] [PDF]
|
|
|
|
 |
|
 D. Lan and D. L. Silver Fenofibrate Induces a Novel Degradation Pathway for Scavenger Receptor B-I Independent of PDZK1 J. Biol. Chem., June 17, 2005; 280(24): 23390 - 23396. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.J. Barter Antiatherogenic Properties of Fibrates Arterioscler Thromb Vasc Biol, June 1, 2005; 25(6): 1095 - 1096. [Full Text] [PDF]
|
|
|
|
|
|
S. N. Chen, C. M. Ballantyne, A. M. Gotto Jr, Y. Tan, J. T. Willerson, and A. J. Marian A Common PCSK9 Haplotype, Encompassing the E670G Coding Single Nucleotide Polymorphism, Is a Novel Genetic Marker for Plasma Low-Density Lipoprotein Cholesterol Levels and Severity of Coronary Atherosclerosis J. Am. Coll. Cardiol., May 17, 2005; 45(10): 1611 - 1619. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Cariou, J.-C. Fruchart, and B. Staels Review: Vascular protective effects of peroxisome proliferator-activated receptor agonists The British Journal of Diabetes & Vascular Disease, May 1, 2005; 5(3): 126 - 132. [Abstract] [PDF]
|
|
|
|
|
|
K. Okrainec, R. Platt, L. Pilote, and M. J. Eisenberg Cardiac medical therapy in patients after undergoing coronary artery bypass graft surgery: A review of randomized controlled trials J. Am. Coll. Cardiol., January 18, 2005; 45(2): 177 - 184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Birjmohun, B. A. Hutten, J. J.P. Kastelein, and E. S.G. Stroes Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: A meta-analysis of randomized controlled trials J. Am. Coll. Cardiol., January 18, 2005; 45(2): 185 - 197. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Whitney, R. A. Krasuski, B. E. Personius, J. E. Michalek, A. M. Maranian, M. W. Kolasa, E. Monick, B. G. Brown, and A. M. Gotto Jr. A Randomized Trial of a Strategy for Increasing High-Density Lipoprotein Cholesterol Levels: Effects on Progression of Coronary Heart Disease and Clinical Events Ann Intern Med, January 18, 2005; 142(2): 95 - 104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Okapcova and D. Gabor The Levels of Soluble Adhesion Molecules in Diabetic and Nondiabetic Patients with Combined Hyperlipoproteinemia and the Effect of Ciprofibrate Therapy Angiology, November 1, 2004; 55(6): 629 - 639. [Abstract] [PDF]
|
|
|
|
 |
|
 N. Marx, H. Duez, J.-C. Fruchart, and B. Staels Peroxisome Proliferator-Activated Receptors and Atherogenesis: Regulators of Gene Expression in Vascular Cells Circ. Res., May 14, 2004; 94(9): 1168 - 1178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Talmud, S. Martin, M.-R. Taskinen, M. H. Frick, M. S. Nieminen, Y. A. Kesaniemi, A. Pasternack, S. E. Humphries, and M. Syvanne APOA5 gene variants, lipoprotein particle distribution, and progression of coronary heart disease: results from the LOCAT study J. Lipid Res., April 1, 2004; 45(4): 750 - 756. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Ou, Z. Ou, D. W. Jones, S. Holzhauer, O. A. Hatoum, A. W. Ackerman, D. W. Weihrauch, D. D. Gutterman, K. Guice, K. T. Oldham, et al. L-4F, an Apolipoprotein A-1 Mimetic, Dramatically Improves Vasodilation in Hypercholesterolemia and Sickle Cell Disease Circulation, May 13, 2003; 107(18): 2337 - 2341. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Barter Review: Reconsidering the value of fibrates: lessons from the trials The British Journal of Diabetes & Vascular Disease, May 1, 2003; 3(3): 162 - 167. [Abstract] [PDF]
|
|
|
|
|
|
P. J. Talmud, S. Martin, G. Steiner, D. M. Flavell, D. B. Whitehouse, S. Nagl, R. Jackson, M.-R. Taskinen, M. H. Frick, M. S. Nieminen, et al. Progression of Atherosclerosis Is Associated With Variation in the {alpha}1-Antitrypsin Gene Arterioscler Thromb Vasc Biol, April 1, 2003; 23(4): 644 - 649. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Ou, J. Ou, A. W. Ackerman, K. T. Oldham, and K. A. Pritchard Jr L-4F, an Apolipoprotein A-1 Mimetic, Restores Nitric Oxide and Superoxide Anion Balance in Low-Density Lipoprotein-Treated Endothelial Cells Circulation, March 25, 2003; 107(11): 1520 - 1524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ma, M. Cilingiroglu, J. D. Otvos, C. M. Ballantyne, A. J. Marian, and L. Chan Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism PNAS, March 4, 2003; 100(5): 2748 - 2753. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Mardones, A. Pilon, M. Bouly, D. Duran, T. Nishimoto, H. Arai, K. F. Kozarsky, M. Altayo, J. F. Miquel, G. Luc, et al. Fibrates Down-regulate Hepatic Scavenger Receptor Class B Type I Protein Expression in Mice J. Biol. Chem., February 28, 2003; 278(10): 7884 - 7890. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Pineda Torra, T. Claudel, C. Duval, V. Kosykh, J.-C. Fruchart, and B. Staels Bile Acids Induce the Expression of the Human Peroxisome Proliferator-Activated Receptor {alpha} Gene via Activation of the Farnesoid X Receptor Mol. Endocrinol., February 1, 2003; 17(2): 259 - 272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
References Circulation, December 17, 2002; 106(25): 3373 - 3421. [Full Text]
|
|
|
|
|
|
I. Pineda Torra, Y. Jamshidi, D. M. Flavell, J.-C. Fruchart, and B. Staels Characterization of the Human PPAR{alpha} Promoter: Identification of a Functional Nuclear Receptor Response Element Mol. Endocrinol., May 1, 2002; 16(5): 1013 - 1028. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Barbier, I. P. Torra, Y. Duguay, C. Blanquart, J.-C. Fruchart, C. Glineur, and B. Staels Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors in Lipid Metabolism and Atherosclerosis Arterioscler Thromb Vasc Biol, May 1, 2002; 22(5): 717 - 726. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Calabresi, M. Gomaraschi, B. Villa, L. Omoboni, C. Dmitrieff, and G. Franceschini Elevated Soluble Cellular Adhesion Molecules in Subjects With Low HDL-Cholesterol Arterioscler Thromb Vasc Biol, April 1, 2002; 22(4): 656 - 661. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Freedman Antioxidant versus Lipid-Altering Therapy -- Some Answers, More Questions N. Engl. J. Med., November 29, 2001; 345(22): 1636 - 1637. [Full Text] [PDF]
|
|
|
|
|
|
P. K. Shah, S. Kaul, J. Nilsson, and B. Cercek Exploiting the Vascular Protective Effects of High-Density Lipoprotein and Its Apolipoproteins: An Idea Whose Time for Testing Is Coming, Part I Circulation, November 6, 2001; 104(19): 2376 - 2383. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Amarenco Hypercholesterolemia, lipid-lowering agents, and the risk for brain infarction Neurology, September 1, 2001; 57(90002): S35 - 44. [Abstract] [Full Text]
|
|
|
|
|
|
S. R. Kapadia, S. E. Nissen, K. M. Ziada, G. Rincon, T. D. Crowe, N. Boparai, J. B. Young, and E. M. Tuzcu Impact of lipid abnormalities in development and progression of transplant coronary disease: a serial intravascular ultrasound study J. Am. Coll. Cardiol., July 1, 2001; 38(1): 206 - 213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Bloomfield Rubins, J. Davenport, V. Babikian, L. M. Brass, D. Collins, L. Wexler, S. Wagner, V. Papademetriou, G. Rutan, and S. J. Robins Reduction in Stroke With Gemfibrozil in Men With Coronary Heart Disease and Low HDL Cholesterol : The Veterans Affairs HDL Intervention Trial (VA-HIT) Circulation, June 12, 2001; 103(23): 2828 - 2833. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Elangbam, R. D. Tyler, and R. M. Lightfoot Peroxisome Proliferator-activated Receptors in Atherosclerosis and Inflammation--An Update Toxicol Pathol, February 1, 2001; 29(2): 224 - 231. [Abstract] [PDF]
|
|
|
|
 |
|
 R. D. Santos, L. I. Ventura, A. C. Sposito, R. Schreiber, J. A.F. Ramires, and R. C. Maranhao The effects of gemfibrozil upon the metabolism of chylomicron-like emulsions in patients with endogenous hypertriglyceridemia Cardiovasc Res, February 1, 2001; 49(2): 456 - 465. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Secondary Prevention by Raising HDL Cholesterol and Reducing Triglycerides in Patients With Coronary Artery Disease : The Bezafibrate Infarction Prevention (BIP) Study Circulation, July 4, 2000; 102(1): 21 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Guyton, M. A. Blazing, J. Hagar, M. L. Kashyap, R. H. Knopp, J. M. McKenney, D. T. Nash, S. D. Nash, and for the Niaspan-Gemfibrozil Study Group Extended-Release Niacin vs Gemfibrozil for the Treatment of Low Levels of High-Density Lipoprotein Cholesterol Arch Intern Med, April 24, 2000; 160(8): 1177 - 1184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Garcia-Moll, F. Coccolo, D. Cole, and J. C. Kaski Serum neopterin and complex stenosis morphology in patients with unstable angina J. Am. Coll. Cardiol., March 15, 2000; 35(4): 956 - 962. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Delerive, K. De Bosscher, S. Besnard, W. Vanden Berghe, J. M. Peters, F. J. Gonzalez, J.-C. Fruchart, A. Tedgui, G. Haegeman, and B. Staels Peroxisome Proliferator-activated Receptor alpha Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-kappa B and AP-1 J. Biol. Chem., November 5, 1999; 274(45): 32048 - 32054. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. H. Knopp Drug Treatment of Lipid Disorders N. Engl. J. Med., August 12, 1999; 341(7): 498 - 511. [Full Text] [PDF]
|
|
|
|
|
|
H. V. Huikuri, V. Jokinen, M. Syvanne, M. S. Nieminen, K. E. J. Airaksinen, M. J. Ikaheimo, J. M. Koistinen, H. Kauma, A. Y. Kesaniemi, S. Majahalme, et al. Heart Rate Variability and Progression of Coronary Atherosclerosis Arterioscler Thromb Vasc Biol, August 1, 1999; 19(8): 1979 - 1985. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Campeau, D. B. Hunninghake, G. L. Knatterud, C. W. White, M. Domanski, S. A. Forman, J. S. Forrester, N. L. Geller, F. L. Gobel, J. A. Herd, et al. Aggressive Cholesterol Lowering Delays Saphenous Vein Graft Atherosclerosis in Women, the Elderly, and Patients With Associated Risk Factors : NHLBI Post Coronary Artery Bypass Graft Clinical Trial Circulation, June 29, 1999; 99(25): 3241 - 3247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. N. Hodis Triglyceride-Rich Lipoprotein Remnant Particles and Risk of Atherosclerosis Circulation, June 8, 1999; 99(22): 2852 - 2854. [Full Text] [PDF]
|
|
|
|
|
|
C. R. Harper and T. A. Jacobson New Perspectives on the Management of Low Levels of High-Density Lipoprotein Cholesterol Arch Intern Med, May 24, 1999; 159(10): 1049 - 1057. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Ballantyne, J. A. Herd, L. L. Ferlic, J. K. Dunn, J. A. Farmer, P. H. Jones, J. R. Schein, and A. M. Gotto Jr Influence of Low HDL on Progression of Coronary Artery Disease and Response to Fluvastatin Therapy Circulation, February 16, 1999; 99(6): 736 - 743. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Syvanne, M. S. Nieminen, M. H. Frick, H. Kauma, S. Majahalme, V. Virtanen, Y. A. Kesaniemi, A. Pasternack, C. Ehnholm, and M.-R. Taskinen Associations Between Lipoproteins and the Progression of Coronary and Vein-Graft Atherosclerosis in a Controlled Trial With Gemfibrozil in Men With Low Baseline Levels of HDL Cholesterol Circulation, November 10, 1998; 98(19): 1993 - 1999. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Staels, J. Dallongeville, J. Auwerx, K. Schoonjans, E. Leitersdorf, and J.-C. Fruchart Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism Circulation, November 10, 1998; 98(19): 2088 - 2093. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Chinetti, S. Griglio, M. Antonucci, I. P. Torra, P. Delerive, Z. Majd, J.-C. Fruchart, J. Chapman, J. Najib, and B. Staels Activation of Proliferator-activated Receptors alpha and gamma Induces Apoptosis of Human Monocyte-derived Macrophages J. Biol. Chem., October 2, 1998; 273(40): 25573 - 25580. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Havel Benefits of Fibrate Drugs in Coronary Heart Disease Patients With Normal Cholesterol Levels Circulation, October 7, 1997; 96(7): 2113 - 2114. [Full Text]
|
|
|
|
|
|
P. Gervois, N. Vu-Dac, R. Kleemann, M. Kockx, G. Dubois, B. Laine, V. Kosykh, J.-C. Fruchart, T. Kooistra, and B. Staels Negative Regulation of Human Fibrinogen Gene Expression by Peroxisome Proliferator-activated Receptor alpha Agonists via Inhibition of CCAAT Box/Enhancer-binding Protein beta J. Biol. Chem., August 31, 2001; 276(36): 33471 - 33477. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Calabresi, M. Gomaraschi, B. Villa, L. Omoboni, C. Dmitrieff, and G. Franceschini Elevated Soluble Cellular Adhesion Molecules in Subjects With Low HDL-Cholesterol Arterioscler Thromb Vasc Biol, April 1, 2002; 22(4): 656 - 661. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Flavell, Y. Jamshidi, E. Hawe, I. Pineda Torra, M.-R. Taskinen, M. H. Frick, M. S. Nieminen, Y. A. Kesaniemi, A. Pasternack, B. Staels, et al. Peroxisome Proliferator-Activated Receptor {alpha} Gene Variants Influence Progression of Coronary Atherosclerosis and Risk of Coronary Artery Disease Circulation, March 26, 2002; 105(12): 1440 - 1445. [Abstract] [Full Text] [PDF]
|
|